首页 国际期刊 医学期刊 期刊详情(非官网)
400-808-1701

Cancer Research And Treatment

Cancer Research And Treatment杂志,由Korean Cancer Association出版,于2001年创刊,4 issues/year,出版语言English,ISSN:1598-2998,E-ISSN:2005-9256。

投稿咨询
Cancer Research And Treatment
Cancer Research And Treatment
Cancer Research And Treatment
SCI SCIE

杂志介绍

JCR分区
Q2
中科院分区
3区
影响因子
4.2
CiteScore
7.7
期刊收录
SCI、SCIE

Cancer Research And Treatment(中文译名:《癌症研究与治疗》),ISSN:1598-2998,EISSN:2005-9256,是Korean Cancer Association出版的国际性学术期刊,创刊于2001年,以4 issues/year形式稳定发行,2026年总发文量约107篇。该刊采用OA开放访问,学科归属为ONCOLOGY。该刊是医学、肿瘤学领域的国际权威刊物,已被SCI(科学引文索引)、SCIE(科学引文索引扩展版)等国际主流学术数据库收录。2026年期刊影响因子达4.2,2025年期刊CiteScore为7.7,2025年期刊自引率约2.4%,在中科院期刊分区体系中位列医学大类3区,在所属学科领域具备高学术影响力与国际认可度。Cancer Research And Treatment长期聚焦医学、肿瘤学及相关产业的技术应用前沿,平均审稿周期>12周,或约稿,审稿流程高效稳定。在稿件录用评判中,该刊将创新性与前沿性作为核心遴选标准,重点收录能够对医学、肿瘤学领域的落地与发展产生实质性推动价值的研究成果。

从全球发文格局来看,South KoreaCHINA MAINLAND、USA、Japan、Taiwan、Italy、Spain等为核心发文国家与地区;SEOUL NATIONAL UNIVERSITY (SNU)SUNGKYUNKWAN UNIVERSITY (SKKU)、NATIONAL CANCER CENTER - KOREA (NCC)、YONSEI UNIVERSITY、UNIVERSITY OF ULSAN、CATHOLIC UNIVERSITY OF KOREA、KOREA UNIVERSITY等高校与科研机构是期刊的主要发文单位。

期刊评价

名词解释:

影响因子(Impact Factor, IF):指该期刊前两年发表的文章,在第三年的平均被引用次数。它反映了期刊的近期平均影响力和热度。

中科院分区:中科院分区表是国内主流的学术期刊分级评价工具,核心意义是建立跨学科可比的统一评价标尺,为职称评审、学位授予、科研立项等科研管理工作提供标准化量化依据,同时帮助科研人员筛选优质期刊、规避学术风险,适配国内本土化的科研评价需求。

期刊分区表

《新锐期刊分区表》(2026年3月发布)

大类学科 小类学科 Top期刊 综述期刊
医学
3区
ONCOLOGY 肿瘤学
3区
否 否

期刊分区表(2025年3月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
2区
ONCOLOGY 肿瘤学
3区
否 否

期刊分区表(2023年12月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
2区
ONCOLOGY 肿瘤学
3区
否 否

JCR分区

2025-2026年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:ONCOLOGY SCIE Q2 108 / 333

67.7

学科:ONCOLOGY SCIE Q2 93 / 333

72.22

2023-2024年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:ONCOLOGY SCIE Q2 91 / 322

71.9

学科:ONCOLOGY SCIE Q1 69 / 322

78.73


中国学者近期发文

1
Elevated SLC3A2 Expression Promotes the Progression of Gliomas and Enhances Ferroptosis Resistance through the AKT/NRF2/GPX4 Axi

Author:Zheng, Yuqian; Zhou, Shaolong; Tao, Yiran; Shi, Zimin; Li, Xiang; Fu, Xudong; Ma, Jian; Hu, Weihua; Liang, Wulong; Wang, Xinjun

Journal: CANCER RESEARCH AND TREATMENT. 2026; Vol. 58, Issue 1, pp. -. DOI: 10.4143/crt.2024.933

2
Adjuvant Chemotherapy in Breast Cancer after Neoadjuvant Therapy: Essential or Optional

Author:Zhang, Di; Yang, Luo; Zheng, Yuan; Zhou, Qi

Journal: CANCER RESEARCH AND TREATMENT. 2026; Vol. 58, Issue 1, pp. 208-220. DOI: 10.4143/crt.2024.1254

3
The Role of Circulating Tumor Cell as a Promising Biomarker in the Evaluation of Pulmonary Nodules: A Prospective Stud

Author:Wang, Shijie; Xu, Changdan; Xu, Xiaohong; Shao, Weipeng; Wang, Guohui; Yang, Xiongtao; Gao, Liwei; Teng, Feng; Sun, Hongliang; Zhao, Yue; Feng, Hongxiang; Zhu, Guangying

Journal: CANCER RESEARCH AND TREATMENT. 2026; Vol. 58, Issue 1, pp. 128-140. DOI: 10.4143/crt.2024.841

4
Deciphering the Risk of Developing Lung Cancer after the Diagnosis of Gastric Cancer with Genetic Evidence: A European and East Asian Populations-Based Mendelian Randomization Analysi

Author:Chen, Jiansheng; Zeng, Aiming; Yu, Yunzhe; Sun, Sida; Liao, Liqun; Huang, Siwei; Yang, Zhongshan; Zhou, Junfeng; Wu, Weijie

Journal: CANCER RESEARCH AND TREATMENT. 2026; Vol. 58, Issue 1, pp. 242-251. DOI: 10.4143/crt.2024.875

5
Synergistic Activation of LEPR and ADRB2 Induced by Leptin Enhances Reactive Oxygen Specie Generation in Triple-Negative Breast Cancer Cell

Author:Liu, Chang; Yu, Jing; Du, Yongjun; Xie, Yu; Song, Xiaofei; Yan, Yan; Wang, Yue; Qin, Junfang

Journal: CANCER RESEARCH AND TREATMENT. 2025; Vol. 57, Issue 2, pp. 457-477. DOI: 10.4143/crt.2024.368

6
Combination Therapy of Pyrotinib and Metronomic Vinorelbine in HER2+Advanced Breast Cancer after Trastuzumab Failure (PROVE): A Prospective Phase 2 Stud

Author:Hao, Chunfang; Wang, Xu; Shi, Yehui; Tong, Zhongsheng; Li, Shufen; Liu, Xiaodong; Zhang, Lan; Zhang, Jie; Meng, Wenjing; Zhang, Li

Journal: CANCER RESEARCH AND TREATMENT. 2025; Vol. 57, Issue 2, pp. 434-442. DOI: 10.4143/crt.2024.340

7
The Oncogenic Role of TNFRSF12A in Colorectal Cancer and Pan-Cancer Bioinformatics Analysi

Author:Wang, Chuyue; Zhao, Yingying; Chen, You; Shi, Ying; Yang, Zhiying; Wu, Weili; Ma, Rui; Wang, Bo; Sun, Yifeng; Yuan, Ping

Journal: CANCER RESEARCH AND TREATMENT. 2025; Vol. 57, Issue 1, pp. 212-228. DOI: 10.4143/crt.2024.408

8
Integrated Transcriptomic Landscape and Deep Learning Based Survival Prediction in Uterine Sarcoma

Author:Song, Yaolin; Li, Guangqi; Zhang, Zhenqi; Liu, Yinbo; Jia, Huiqing; Zhang, Chao; Wang, Jigang; Hu, Yanjiao; Hao, Fengyun; Liu, Xianglan; Xie, Yunxia; Ma, Ding; Li, Ganghua; Tai, Zaixian; Xing, Xiaoming

Journal: CANCER RESEARCH AND TREATMENT. 2025; Vol. 57, Issue 1, pp. 250-266. DOI: 10.4143/crt.2024.343

9
A Single-Arm Phase II Clinical Trial of Fulvestrant Combined with Neoadjuvant Chemotherapy of ER+/HER2-Locally Advanced Breast Cancer: Integrated Analysis of 18F-FES PET-CT and Metabolites with Treatment Respons

Author:Shao, Qing; Zhang, Ningning; Pan, Xianjun; Zhou, Wenqi; Wang, Yali; Chen, Xiaoliang; Wu, Jing; Zeng, Xiaohua

Journal: CANCER RESEARCH AND TREATMENT. 2025; Vol. 57, Issue 1, pp. 126-139. DOI: 10.4143/crt.2023.1251


在线咨询

Cancer Research And Treatment

国际简称:CANCER RES TREAT参考译名:癌症研究与治疗

年发文量:107 CiteScore:7.7 是否预警:否 Gold OA文章占比:99.43% 研究类文章占比:97.20%

杂志社联系方式:RM 1824, GWANGHWAMUN OFFICIA, 92 SAEMUNAN-RO, JONGNO-GU, SEOUL, SOUTH KOREA, 110-999

Cancer Research And Treatment